ANG ‐Modified Liposomes Coloaded With α‐Melittin and Resveratrol Induce Apoptosis and Pyroptosis in Glioblastoma Cells by Impeding Wnt/β‐Catenin Signaling
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70437 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Hai-Qian Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Changchun Veterinary Research Institute, Chinese Academy of Agricultural Science, Changchun, China. Hauptthemen laut MEDLINE: Resveratrol, Glioblastoma, Pyroptosis, Apoptosis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Jilin Province Science and Technology Development Plan Project.
Abstract (Originalsprache)
Main Problem Glioblastoma (GB) is one of the most prevalent and devastating types of brain cancer for which efficient treatments are currently lacking because of limitations such as antitumor efficacy, brain delivery, tumor selectivity, and drug resistance. A promising strategy to overcome these obstacles is developing anticancer agents that can be delivered to GB tissues to inhibit tumors with low toxicity to normal brain tissue.
Methods
We developed liposomes encapsulating resveratrol (RES), a polyphenolic compound, and α‐melittin (α‐MEL), which is composed of melittin conjugated with an amphiphilic α‐helical peptide at its N‐terminus. RES‐, α‐MEL‐, and α‐MEL‐RES‐loaded liposomes (Lips) were modified with Angiopep‐2 (ANG). The effects of the above liposomes on GB cells were assessed, and the possible mechanisms were analyzed.
Results
ANG‐modified α‐MEL‐RES‐Lips treatment facilitated the passage of these agents through the blood–brain barrier (BBB), increased tumor targeting, and significantly reduced α‐MEL‐associated hemolysis. The combined management of α‐MEL with RES impeded GB cell growth and prolonged the lifespan of GB tumor‐bearing model mice. α‐MEL‐RES‐Lips treatment triggered GB cell apoptosis and induced pyroptosis‐associated protein expressions of gasdermin‐D (GSDMD), gasdermin E (GSDME), cleaved caspase 3, and NLR family pyrin domain containing 3 (NLRP3), and inhibited epithelial–mesenchymal transition (EMT) by modulating the Wnt/β‐catenin signaling pathway.
Conclusion
ANG‐modified α‐MEL‐RES‐Lips might be a potential nanosystem for GB therapy, and polyphenolic compounds combined with antimicrobial peptides may promote the induction of apoptosis, pyroptosis, and the apoptosis–pyroptosis switch in GB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Changchun Veterinary Research Institute, Chinese Academy of Agricultural Science, Changchun, China.
- The Second Hospital of Jilin University, Changchun, China.
- State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, AMMS, Beijing, China.
- Basic College of Medicine, Jilin Medical University, Jilin, China.
ORCID-Profile: Hai-Qian Zhang
Förderung
- the Jilin Province Science and Technology Development Plan Project
Zitieren
APA
Zhang, H. Q., Wang, Y., Geng, X., Dong, M., Liu, Z., Sun, C., Yu, K., Xin, W., Xu, Y., Xu, N., & Liu, W. (2025). ANG ‐Modified Liposomes Coloaded With α‐Melittin and Resveratrol Induce Apoptosis and Pyroptosis in Glioblastoma Cells by Impeding Wnt/β‐Catenin Signaling. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70437
Vancouver
Zhang HQ, Wang Y, Geng X, Dong M, Liu Z, Sun C, et al. ANG ‐Modified Liposomes Coloaded With α‐Melittin and Resveratrol Induce Apoptosis and Pyroptosis in Glioblastoma Cells by Impeding Wnt/β‐Catenin Signaling. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70437
BibTeX
@article{Zhang2025,
author = {Zhang, Hai-Qian and Wang, Yan and Geng, Xiao and Dong, Mingxin and Liu, Ziwei and Sun, Chengbiao and Yu, Kaikai and Xin, Wenwen and Xu, Ye and Xu, Na and Liu, Wensen},
title = {ANG ‐Modified Liposomes Coloaded With α‐Melittin and Resveratrol Induce Apoptosis and Pyroptosis in Glioblastoma Cells by Impeding Wnt/β‐Catenin Signaling},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70437}
}
EUVIMED